United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 6.5mmol) effervescent tablets bpc 1968 (actavis uk ltd - potassium bicarbonate; potassium acid tartrate - effervescent tablet - 500mg ; 300mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

stirling anglian pharmaceuticals ltd - naproxen - effervescent tablet - 250mg

Ireland - English - HPRA (Health Products Regulatory Authority)

reckitt benckiser ireland ltd - acetylsalicylic acid - effervescent tablet - 500 milligram(s) - salicylic acid and derivatives; acetylsalicylic acid

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - ascorbic acid; zinc citrate trihydrate - effervescent tablet - 1000/10mg milligram(s) - ascorbic acid (vitamin c), combinations

Ireland - English - HPRA (Health Products Regulatory Authority)

stirling anglian pharmaceuticals ltd - naproxen - effervescent tablet - 250 milligram(s) - propionic acid derivatives; naproxen

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - cyclosporine (unii: 83hn0gtj6d) (cyclosporine - unii:83hn0gtj6d) - cyclosporine 100 mg - cyclosporine capsules, usp are indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. it is always to be used with adrenal corticosteroids. the drug may also be used in the treatment of chronic rejection in patients previously treated with other immunosuppressive agents.    cyclosporine capsules are contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation.

United States - English - NLM (National Library of Medicine)

padagis us llc - cyclosporine (unii: 83hn0gtj6d) (cyclosporine - unii:83hn0gtj6d) - cyclosporine 50 mg in 1 ml - cyclosporine is indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. it is always to be used with adrenal corticosteroids. the drug may also be used in the treatment of chronic rejection in patients previously treated with other immunosuppressive agents. because of the risk of anaphylaxis, cyclosporine injection should be reserved for patients who are unable to take the soft gelatin capsules or oral solution. cyclosporine injection is contraindicated in patients with a hypersensitivity to cyclosporine and/or cremophor® el (polyoxyethylated castor oil).

United States - English - NLM (National Library of Medicine)

eon labs, inc. - cyclosporine (unii: 83hn0gtj6d) (cyclosporine - unii:83hn0gtj6d) - cyclosporine 25 mg - cyclosporine capsules usp (modified) are indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. cyclosporine capsules usp (modified) have been used in combination with azathioprine and corticosteroids. cyclosporine capsules usp (modified) are indicated for the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate. cyclosporine capsules usp (modified) can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alone. cyclosporine capsules usp (modified) are indicated for the treatment of adult, nonimmunocompromised patients with severe (i.e., extensive and/or disabling), recalcitrant, plaque psoriasis who have failed to respond to at least one systemic therapy (e.g., puva, retinoids, or methotrexate) or in patients for whom other systemic therapies are contraindicated, or cannot be tolerated. while rebound rarely occurs, most patie

United States - English - NLM (National Library of Medicine)

american health packaging - cyclosporine (unii: 83hn0gtj6d) (cyclosporine - unii:83hn0gtj6d) - cyclosporine 25 mg - cyclosporine capsules, usp (non-modified) are indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. it is always to be used with adrenal corticosteroids. the drug may also be used in the treatment of chronic rejection in patients previously treated with other immunosuppressive agents. cyclosporine capsules are contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation.

United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - cyclosporine (unii: 83hn0gtj6d) (cyclosporine - unii:83hn0gtj6d) - cyclosporine 25 mg - cyclosporine capsules usp modified are indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. cyclosporine capsules usp modified have been used in combination with azathioprine and corticosteroids. cyclosporine capsules usp modified are indicated for the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate. cyclosporine capsules usp modified can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alone. cyclosporine capsules usp modified are indicated for the treatment of adult, nonimmunocompromised patients with severe (i.e., extensive and/or disabling), recalcitrant, plaque psoriasis who have failed to respond to at least one systemic therapy (e.g., puva, retinoids, or methotrexate) or in patients for whom other systemic therapies are contraindicated, or cannot be tolerated. while rebound rarely occurs, most patients will experience relapse with cyclosporine capsules usp modified as with other therapies upon cessation of treatment. cyclosporine capsules usp modified are contraindicated in patients with a hypersensitivity to cyclosporine or to any of the ingredients of the formulation. rheumatoid arthritis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules usp modified. psoriasis patients who are treated with cyclosporine capsules usp modified should not receive concomitant puva or uvb therapy, methotrexate or other immunosuppressive agents, coal tar or radiation therapy. psoriasis patients with abnormal renal function, uncontrolled hypertension, or malignancies should not receive cyclosporine capsules usp modified.